虚拟现实对阿片类药物使用障碍住院患者的试点研究
Herbert J Greenwald1,2, Amy Berger3, Ronan L H Wilson3
13D Therapy, LLC, Beverly, Massachusetts, USA.
The American journal on addictions
|March 2, 2024
概括
虚拟现实疗法 (3D Therapy Thrive) 在患有阿片类药物使用障碍 (OUD) 的患者中,有望减少抑郁,紧张和渴望等阿片类药物戒断症状. 这项试点研究表明了入院OUD治疗的可行性和初步有效性.
科学领域:
- 成 药物 药物 药物 药物
- 数字健康数字健康
- 精神病学是一个精神病学.
背景情况:
- 住院阿片类药物戒断管理可能受到由于戒断症状而导致患者早期戒断的阻碍.
- 片类药物使用障碍 (OUD) 治疗的保留是一个重大挑战.
- 需要新的干预措施来支持患者在急性稳定期间.
研究的目的:
- 为了评估虚拟现实 (VR) 干预的可行性和初步有效性,3D Therapy Thrive (3DTT).
- 评估3DTT对OUD患者情绪,紧张和渴望的影响.
- 探索患者的满意度和与VR治疗相关的副作用.
主要方法:
- 一项试点研究涉及32名被诊断患有OUD的住院患者.
- 参与者接受了最多两次3D疗法勃发展 (3DTT) VR干预的会议.
- 标准化问卷评估了干预前后的满意度,副作用,情绪,紧张和渴望.
主要成果:
- 参与者满意度高 (94%),没有报告的副作用.
- 与基线相比,抑郁,紧张和渴望的显著减少 (p < 0.001).
- 通过53%的招聘率和58%的治疗方案完成来证明可行性.
结论:
- 3D Therapy Thrive (3DTT) 是一种可行且潜在有效的干预措施,用于改善OUD住院患者的治疗结果.
- 虚拟现实疗法在缓解关键戒断症状方面表现有前途.
- 需要进一步的随机对照试验来证实治疗延续和症状减轻的疗效.
相关概念视频
The Placebo Effect
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


